Table II.
Upsteam and downstream of hsa-miR-17 in three networks of serous ovarian cancer.
| Upstream | Downstream | |||||
|---|---|---|---|---|---|---|
| Differentially expressed network | Related network | Global network | miRNA | Differentially expressed network | Related network | Global network |
| MYC | CCND1 | CCND1 | miR-17 | PTEN | CCND1 | APP |
| E2F1 | E2F1 | MYC | BCL2 | BCL2 | ||
| ESR1 | ESR1 | RUNX1 | BCL2L11 | |||
| MYC | MYC | CCND2 | BIM | |||
| MYCN | MYCN | CDKN1A | BMPR2 | |||
| NFKB1 | NFKB1 | E2F1 | CCL1 | |||
| TNF | NKX2-5 | CXCL8 | CCND1 | |||
| SPI1 | SMAD4 | CCND2 | ||||
| STAT5B | MYC | CDKN1A | ||||
| TLX1 | PTEN | DNAJC27 | ||||
| TLX3 | RB1 | E2F1 | ||||
| TNF | TGFBR2 | E2F3 | ||||
| THBS1 | S1PR1 | |||||
| VEGFA | FBXO31 | |||||
| VIM | GAB1 | |||||
| E2F3 | GPR137B | |||||
| ICAM1 | ||||||
| CXCL8 | ||||||
| JAK1 | ||||||
| MAP3K12 | ||||||
| MAPK9 | ||||||
| MEF2D | ||||||
| MUC17 | ||||||
| MYC | ||||||
| NCOA3 | ||||||
| NPAT | ||||||
| NABP1 | ||||||
| PKD2 | ||||||
| PRKD1 | ||||||
| PRKD2 | ||||||
| PTEN | ||||||
| PTPRO | ||||||
| RB1 | ||||||
| RBL1 | ||||||
| YES1 | ||||||
| ZNFX1 | ||||||
hsa, human; miRNA, microRNA; APP, amyloid beta precursor protein; BCL2, apoptosis regulator; BCL2L11, BCL2 like 11; BMPR2, bone morphogenetic protein receptor type 2; CCL1, C-C motif chemokine ligand 1; CCND1, cyclin D1; CCND2, cyclin D2; CDKN1A, cyclin dependent kinase inhibitor 1A; DNAJC27, DnaJ heat shock protein family (Hsp40) member C27; E2F1, E2F transcription factor 1; E2F3, E2F transcription factor 3; S1PR1, sphingosine-1-phosphate receptor 1; ESR1, estrogen receptor 1; FBXO31, F-box protein 31; GAB1, GRB2 associated binding protein 1; GPR137B, G protein-coupled receptor 137B; ICAM1, intercellular adhesion molecule 1; CXCL8, C-X-C motif chemokine ligand 8; JAK1, Janus kinase 1; MAP3K12, mitogen-activated protein kinase kinase kinase 12; MAPK9, mitogen-activated protein kinase 9; MEF2D, myocyte enhancer factor 2D; MUC17, mucin 17, cell surface associated; MYC, MYC proto-oncogene, bHLH transcription factor; MYCN, MYCN proto-oncogene, bHLH transcription factor; NCOA3, nuclear receptor coactivator 3; NFKB1, nuclear factor-κB subunit 1; NKX2-5, NK2 homeobox 5; NPAT, nuclear protein, coactivator of histone transcription; NABP1, nucleic acid binding protein 1; PKD2, polycystin 2, transient receptor potential cation channel; PRKD1, protein kinase D1; PRKD2, protein kinase D2; PTEN, phosphatase and tensin homolog; PTPRO, protein tyrosine phosphatase, receptor type O; RB1, RB transcriptional corepressor 1; RBL1, RB transcriptional corepressor like 1; RUNX1, runt related transcription factor 1; SMAD4, SMAD family member 4; SPI1, Spi-1 proto-oncogene; STAT5B, signal transducer and activator of transcription 5B; TGFBR2, transforming growth factor beta receptor 2; THBS1, thrombospondin 1; TLX1, T-cell leukemia homeobox 1; TLX3, T-cell leukemia homeobox 3; TNF, tumor necrosis factor; VEGFA, vascular endothelial growth factor A; VIM, vimentin; YES1, YES proto-oncogene 1, Src family tyrosine kinase; ZNFX1, zinc finger NFX1-type containing 1.